Economic evaluation of enoxaparin sodium versus heparin in unstable angina- A French sub-study of the ESSENCE trial

Objectives: To pet-form an evaluation from the societal perspective of the cost of treatment with enoxaparin sodium versus unfractionated heparin (UFH ) in patients with unstable angina and non-Q wave myocardial infarction in France. Design: Four complementary cost-minimisation analyses based on the results of the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronar y Events (ESSENCE) international trial were conducted. We assessed differen ces in medical resource consumption and in duration of hospital stay in the whole study population (n = 3171) and for the French patients (n = 133). Results: Results were consistent for the study group as a whole and for the French subgroup. Among patients treated with enoxaparin sodium, there was a statistically significant reduction in the use of angiography and percuta neous transluminal coronary angioplasty (whole group study: p = 0.024 and 0 .006, respectively) and a trend towards shorter lengths of hospital stay. T he differences in angiography and angioplasty rates led to estimated averag e net cost savings with enoxaparin sodium of French Francs (FF)1555 per tre ated patient (whole study population) and FF9993 (French subgroup) [1996 va lues]. The analyses based on the duration of hospital stay resulted in esti mated net cost savings with enoxaparin sodium of between FF1014 per treated patient (whole study population) and FF2804 (French subgroup). Conclusion: Our study confirmed earlier results which show that enoxaparin sodium is cost saving in the treatment of unstable angina.